PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EXEL vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EXEL and CRSP is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

EXEL vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

150.00%200.00%250.00%300.00%NovemberDecember2025FebruaryMarchApril
210.24%
175.44%
EXEL
CRSP

Key characteristics

Sharpe Ratio

EXEL:

1.67

CRSP:

-0.70

Sortino Ratio

EXEL:

2.51

CRSP:

-0.94

Omega Ratio

EXEL:

1.35

CRSP:

0.90

Calmar Ratio

EXEL:

0.98

CRSP:

-0.45

Martin Ratio

EXEL:

9.22

CRSP:

-1.40

Ulcer Index

EXEL:

6.27%

CRSP:

27.31%

Daily Std Dev

EXEL:

34.69%

CRSP:

54.85%

Max Drawdown

EXEL:

-97.38%

CRSP:

-85.11%

Current Drawdown

EXEL:

-27.43%

CRSP:

-81.52%

Fundamentals

Market Cap

EXEL:

$9.88B

CRSP:

$3.37B

EPS

EXEL:

$1.76

CRSP:

-$4.34

PEG Ratio

EXEL:

2.27

CRSP:

-0.21

Total Revenue (TTM)

EXEL:

$1.74B

CRSP:

$36.12M

Gross Profit (TTM)

EXEL:

$1.69B

CRSP:

-$32.01M

EBITDA (TTM)

EXEL:

$650.08M

CRSP:

-$311.55M

Returns By Period

In the year-to-date period, EXEL achieves a 7.33% return, which is significantly higher than CRSP's -1.40% return.


EXEL

YTD

7.33%

1M

-2.48%

6M

36.20%

1Y

56.69%

5Y*

14.47%

10Y*

27.74%

CRSP

YTD

-1.40%

1M

-7.86%

6M

-18.85%

1Y

-36.03%

5Y*

-4.23%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EXEL vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EXEL
The Risk-Adjusted Performance Rank of EXEL is 9393
Overall Rank
The Sharpe Ratio Rank of EXEL is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of EXEL is 9393
Sortino Ratio Rank
The Omega Ratio Rank of EXEL is 9393
Omega Ratio Rank
The Calmar Ratio Rank of EXEL is 8787
Calmar Ratio Rank
The Martin Ratio Rank of EXEL is 9595
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 2121
Overall Rank
The Sharpe Ratio Rank of CRSP is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1818
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 2323
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2828
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 1818
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EXEL vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EXEL, currently valued at 1.67, compared to the broader market-2.00-1.000.001.002.00
EXEL: 1.67
CRSP: -0.70
The chart of Sortino ratio for EXEL, currently valued at 2.51, compared to the broader market-6.00-4.00-2.000.002.004.00
EXEL: 2.51
CRSP: -0.94
The chart of Omega ratio for EXEL, currently valued at 1.35, compared to the broader market0.501.001.502.00
EXEL: 1.35
CRSP: 0.90
The chart of Calmar ratio for EXEL, currently valued at 1.60, compared to the broader market0.001.002.003.004.00
EXEL: 1.60
CRSP: -0.45
The chart of Martin ratio for EXEL, currently valued at 9.22, compared to the broader market-5.000.005.0010.0015.0020.00
EXEL: 9.22
CRSP: -1.40

The current EXEL Sharpe Ratio is 1.67, which is higher than the CRSP Sharpe Ratio of -0.70. The chart below compares the historical Sharpe Ratios of EXEL and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.00NovemberDecember2025FebruaryMarchApril
1.67
-0.70
EXEL
CRSP

Dividends

EXEL vs. CRSP - Dividend Comparison

Neither EXEL nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EXEL vs. CRSP - Drawdown Comparison

The maximum EXEL drawdown since its inception was -97.38%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for EXEL and CRSP. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-8.72%
-81.52%
EXEL
CRSP

Volatility

EXEL vs. CRSP - Volatility Comparison

The current volatility for Exelixis, Inc. (EXEL) is 9.64%, while CRISPR Therapeutics AG (CRSP) has a volatility of 23.47%. This indicates that EXEL experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
9.64%
23.47%
EXEL
CRSP

Financials

EXEL vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Exelixis, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab